Back to News
Market Impact: 0.4
Caribou Biosciences To Halt Two CAR-T Programs, Cut Workforce; Shares Plunge
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Caribou Biosciences announced plans to discontinue further development of two allogeneic CAR-T cell therapy programs. The article excerpt identifies vispa-cel, intended for relapsed or refractory B-cell non-Hodgkin lymphoma, but cuts off before providing details about the second program or the rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.50
Ticker Sentiment
CRBU-0.80
More News
- Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
- Samsung Q3 profit surges to record high, but misses lofty expectations
- Brazil is having its Argentina moment. How to play it